A new medical-record study found no statistically clear difference in cardiovascular events between semaglutide and tirzepatide in adults with established artery disease, overweight or obesity, and no diabetes. That finding leaves an important question open: which medicine, if either, prevents more heart attacks and strokes in this population?
The paper by Mohamed Doma and colleagues appeared online on October 30, 2026. It compared matched groups of 5,665 people each. Its most useful contribution is a closer look at a specific cardiovascular population, rather than another ranking by weight loss. Unequal follow-up and missing treatment-exposure information limit how confidently its findings can guide that comparison.
Who was compared, and what counted as an event?
The researchers used the TriNetX health-record network, selecting adults aged 45 or older with a BMI of at least 27 and documented atherosclerotic cardiovascular disease, or ASCVD. People with diabetes were excluded. Propensity-score matching balanced recorded characteristics such as age, medical conditions and other medicines. It cannot balance factors that were absent from the records.
The semaglutide group was restricted to prescriptions for 2.4 mg; tirzepatide prescriptions were included regardless of dose because dose-level information was inconsistent. These describe the research exposure, not instructions for choosing or switching treatment. The comparison therefore does not represent two fixed, equally documented regimens.
The primary outcome combined death from any cause, heart attack, ischemic stroke, worsening heart failure and coronary revascularization by a catheter procedure. A secondary three-component outcome included all-cause death, heart attack and ischemic stroke. The definition matters: “MACE,” short for major adverse cardiovascular events, does not always describe the same collection of events. The study methods specify the components used here.
No clear difference is not proof of equal protection
For the primary five-component outcome, the reported hazard ratio for semaglutide versus tirzepatide was 1.03, with a 95% confidence interval of 0.94 to 1.12. For the three-component outcome it was 1.04, with an interval of 0.95 to 1.14. Both intervals cross 1, the point indicating no difference in the modeled hazard. Neither result established a statistically significant advantage.
Those intervals still allow differences in either direction. An observational finding that fails to detect a difference cannot establish therapeutic equivalence, and the authors explicitly warn against that interpretation. Nor does this study compare either medicine with taking neither. Our guide to randomized and real-world evidence explains why these designs answer different questions.
Why the two groups had different observation time
Follow-up lasted up to 900 days, but the average was 497 days for semaglutide and 380 for tirzepatide. Later uptake of tirzepatide contributed to its shorter observation window. Raw event percentages across those windows are not equal-duration risks and should not be subtracted to calculate an individual treatment benefit.
The time-to-event model accounts for different observed follow-up, but that does not remove every concern. Treatment started in different calendar periods, and short observation may miss differences that emerge later. The records also lacked reliable information about adherence, persistence, stopping treatment and achieved dose. A prescription does not establish how much medicine someone actually received.
Outcomes were identified through diagnostic and procedural codes rather than independently adjudicated trial events. Misclassification and unmeasured differences between patients remain possible. Longitudinal weight data were unavailable, so the analysis cannot explain cardiovascular findings through the amount of weight lost.
How this fits alongside SELECT and STEER
SELECT randomized 17,604 adults with cardiovascular disease, BMI of at least 27 and no diabetes to weekly semaglutide 2.4 mg or placebo. Over a mean 39.8 months, semaglutide reduced its primary cardiovascular endpoint, with a hazard ratio of 0.80. SELECT included cardiovascular death, nonfatal heart attack and nonfatal stroke; the new study uses all-cause death. Their event rates cannot be ranked as if they measured identical outcomes.
SELECT supports semaglutide versus placebo; it does not establish superiority over tirzepatide. The FDA approved a cardiovascular indication for Wegovy injection in March 2024. The new observational paper is not a regulatory decision.
Another observational study, STEER, found an association favoring semaglutide using US insurance claims. Novo Nordisk funded that study and participated in its design, interpretation and manuscript development. Doma and colleagues reported no funding, while disclosing author industry relationships. Different datasets, populations and analytic choices can produce conflicting associations; neither observational comparison settles a randomized head-to-head question.
What to take to a treatment discussion
Ask which outcome matters for the proposed treatment and whether the supporting evidence matches your medical history. Weight reduction, heart-failure outcomes and prevention of artery-related events are separate questions. The semaglutide and tirzepatide profiles provide wider context; our direct weight-loss comparison covers a different endpoint.
This paper gives a reason to resist declaring a cardiovascular winner from routine-care records. A stronger answer needs prospective comparative evidence, adequate follow-up and clear treatment-exposure data. It does not supply a dose conversion or a reason to switch a prescribed medicine on your own.


